Details of the Drug

General Information of Drug (ID: DM6ENSJ)

Drug Name

Tralokinumab

Synonyms

CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Approved	[1]
Ulcerative colitis	DD71	Phase 3	[2]
Asthma	CA23	Phase 1/2	[3]

Affected Organisms

Humans and other mammals

ATC Code

D11AH07: Tralokinumab

D11AH: Agents for dermatitis, excluding corticosteroids

D11A: OTHER DERMATOLOGICAL PREPARATIONS

D11: OTHER DERMATOLOGICAL PREPARATIONS

D: DERMATOLOGICALS

Drug Type

Monoclonal antibody

Sequence

>heavy chain
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNY
GQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTV
SSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQ
EGNVFSCSVMHEALHNHYTQKSLSLSLGK
>light chain
SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPER
FSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVLGQPKAAPSVTLF
PPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYL
SLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5-8 days [4]
Bioavailability: The bioavailability of drug is 76% [4]
Clearance: The clearance of drug is 0.149 L/day [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 22 days [4]
Metabolism: The drug is metabolized via the catabolism to smaller peptides and amino acids [4]
Vd: The volume of distribution (Vd) of drug is 4.2 L [4]

Cross-matching ID

UNII: GK1LYB375A
DrugBank ID: DB12169
TTD ID: D0I1ZY

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Inhibitor	[6]
Interleukin 13 receptor alpha-2 (IL13RA2)	TTMPZ7V	I13R2_HUMAN	Modulator	[7]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Atopic dermatitis

ICD Disease Classification

EA80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 13 receptor alpha-2 (IL13RA2)	DTT	IL13RA2	4.40E-01	2.46	1
Interleukin 13 receptor alpha-2 (IL13RA2)	DTT	IL13RA2	5.77E-05	4.14	2.11

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761180.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001).
3	ClinicalTrials.gov (NCT02085473) A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers
4	Health Canada Product Monograph: Adtralza (tralokinumab) for subcutaneous injection
5	EMA Summary of Product Characteristics: Adtralza (tralokinumab) for subcutaneous injection
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.